Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT05215574
Official study title

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study summary

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNGM831 and NGM831 plus pembrolizumab (KEYTRUDA®)

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Mesothelioma · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 10, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?9 U.S. locations

Locations may change over time.

Who runs it?NGM Biopharmaceuticals, Inc

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
NGM Biopharmaceuticals, Inc
Interventions being studied
Drug: NGM831; Drug: NGM831 plus pembrolizumab (KEYTRUDA®); Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Mesothelioma→
Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
  • Adequate bone marrow, kidney and liver function
  • Performance status of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment targeting ILT3.
  • Prior treatment targeting LAIR1.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • NGM Clinical Study SiteGilbert, Arizona
  • NGM Clinical Study SiteLos Angeles, California
  • NGM Clinical Study SiteSarasota, Florida
  • NGM Clinical Study SiteTampa, Florida
  • NGM Clinical Study SiteGrand Rapids, Michigan
  • NGM Clinical Study SiteNew York, New York
  • NGM Clinical Study SiteOklahoma City, Oklahoma
  • NGM Clinical Study SiteAustin, Texas
  • NGM Clinical Study SiteHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 10, 2024. Always confirm current availability with the study team.

View original record ↗